Copd new guidelines
Reading File
The GOLD 2025 guidelines for COPD emphasize individualized assessment, updated pharmacotherapy, and non-pharmacological management. Let me pull the latest from both textbooks and current literature.
Searching sources...
Finding Sources
Searching PubMed
"COPD" AND "GOLD guidelines"
Searching the Web
GOLD COPD guidelines 2025 2026 new updates
Reading Web Page
https://www.chestphysician.org/gold-2026-updates-in-global-s…
Finding Sources
Searching PubMed
"chronic obstructive pulmonary disease" AND "triple therapy" AND "eosinophil"
Here is a comprehensive summary of the GOLD 2026 COPD Guidelines - the most current update, released November 2025:
GOLD 2026 COPD Guidelines - Key Updates
The GOLD 2026 report is a major revision adding 330 new references (vs. 164 in 2025) from literature published January 2024 - July 2025.
1. Core Conceptual Shift: "Disease Activity"
GOLD 2026 reframes COPD from a static airflow limitation disorder to a biologically active, modifiable disease. The new therapeutic goal is achieving a "low disease activity state" - defined by:
- No exacerbations
- Controlled symptoms
- Minimized disease progression
Spirometry (postbronchodilator FEV1/FVC < 0.70) remains essential for diagnosis but is now interpreted alongside clinical features and imaging.
2. Revised ABE Classification
The classic ABCD tool is now the refined ABE framework:
| Group | Description | Initial Treatment |
|---|---|---|
| A | Low symptoms, low exacerbation risk | Any bronchodilator (monotherapy) |
| B | High symptoms, low exacerbation risk | LABA + LAMA (dual bronchodilation) |
| E | High exacerbation risk (≥1 moderate/severe exacerbation) | LABA + LAMA |
Key change: The threshold for Group E is now any single moderate or severe exacerbation in the prior year (previously required ≥2 moderate OR ≥1 severe). Even one exacerbation is now enough to trigger escalation to dual bronchodilation.
3. Pharmacotherapy Updates
Initial Therapy
- Group A: Single bronchodilator
- Group B & E: LABA/LAMA preferred over LABA/ICS as initial therapy
- LABA/ICS monotherapy is explicitly discouraged without asthma features - it carries higher pneumonia risk and weaker exacerbation prevention vs. dual bronchodilation
Escalation to Triple Therapy (ICS/LABA/LAMA)
Triple therapy is the preferred next step for Group E patients who still exacerbate on LABA/LAMA, guided by blood eosinophil counts (BEC):
| BEC | ICS Recommendation |
|---|---|
| ≥ 300 cells/µL | Strong indication for ICS addition |
| 100-299 cells/µL | Consider ICS |
| < 100 cells/µL | ICS not recommended |
Supported by IMPACT, ETHOS, TRINITY, and TRIBUTE trials. A 2026 meta-analysis (PMID: 42237170) confirms triple therapy superiority over dual therapy for exacerbation reduction.
ICS De-escalation
When risks outweigh benefits, ICS withdrawal is endorsed - but explicitly discouraged if BEC ≥ 300 cells/µL due to high relapse risk.
4. Biologic Therapies - Major Addition
GOLD 2026 formally integrates biologics into the escalation algorithm for the first time at Level A evidence:
- Dupilumab (anti-IL-4/IL-13): For patients with COPD + chronic bronchitis + BEC ≥ 300 cells/µL uncontrolled on triple therapy. Supported by BOREAS and NOTUS trials - reduces moderate-to-severe exacerbations by 30-34% and improves FEV1.
- Mepolizumab (anti-IL-5): Evidence in eosinophilic phenotypes.
A new figure (Figure 3.11) was added specifically outlining biologic therapy evidence.
5. Diagnosis & Case-Finding
- Two new figures added: Figure 2.8 (factors associated with COPD underdiagnosis) and Figure 2.9 (algorithm for COPD case-finding)
- Updated Screening and Case-finding section reflecting new evidence
- Emphasis on early diagnosis beyond symptomatic patients
6. Exacerbation Management
- Updated definitions and severity classifications
- Refined criteria for outpatient vs. inpatient treatment decisions
- High-flow nasal oxygen and noninvasive ventilation now explicitly incorporated
- Structured post-exacerbation follow-up is mandated to reassess and optimize maintenance therapy
- Exacerbation frequency and recovery time are highlighted as markers of disease activity
7. Non-Pharmacological Therapy
- Pulmonary rehabilitation: Reaffirmed as essential; new appendix on non-pharmacological evidence added
- Smoking cessation: Remains the most impactful intervention to slow FEV1 decline
- Vaccinations updated:
- Influenza: Annual vaccination recommended
- RSV vaccination: New recommendation included for people with COPD
- Pneumococcal, COVID-19, and Tdap also recommended
- Lung cancer screening: Annual low-dose CT for patients with smoking history
8. Comorbidities (Revised Chapter)
- Substantially revised chapter on multimorbidity (Chapter 5)
- Common comorbidities: hypertension, ischemic heart disease, HF, atrial fibrillation, bronchiectasis, depression, anxiety
- Comorbidities should be treated per their own guidelines independently of COPD
- A 2025 meta-analysis (PMID: 40684148) on triple therapy shows benefits for cardiovascular mortality in moderate-severe COPD
9. New Chapter: AI and Emerging Technologies (Chapter 6)
A completely new chapter on artificial intelligence and digital health tools in COPD - covering diagnostics, monitoring, and precision phenotyping.
Quick Reference Summary
| Feature | GOLD 2025 | GOLD 2026 |
|---|---|---|
| Group E threshold | ≥2 moderate or ≥1 severe exacerbation | ≥1 moderate or severe exacerbation |
| Biologic therapy | Cautious mention | Level A evidence, integrated into algorithm |
| Disease concept | Airflow limitation | Disease activity as therapeutic target |
| ICS de-escalation | Endorsed | Endorsed, discouraged if BEC ≥300 |
| RSV vaccination | Not mentioned | Recommended |
| AI chapter | Absent | New Chapter 6 |
The full GOLD 2026 report is available at goldcopd.org and the key changes summary from the GOLD Science Committee is a useful quick reference.
This is a shared conversation. Sign in to Orris to start your own chat.